All Issue

2025 Vol.55, Issue 2 Preview Page

Review Article

Fosfomycin, an Antibacterial Agent for Urinary Tract Infections
Jannatul Mawa Mim1
,
Shohana Ferdoush1
,
Fatema Hossain Lia2
,
Md. Towfiquzzaman2
,
Md. Robin Mia1
,
Mohammad Saydur Rahman1*
,
Young-Sang Koh34*
1Department of Pharmacy, Jagannath University, Dhaka-1100, Bangladesh
2Department of Pharmacy, State University of Bangladesh, Dhaka-1205, Bangladesh
3Department of Microbiology and Immunology, College of Medicine, Jeju National University, Jeju 63243, Republic of Korea
4Jeju Research Center for Natural Medicine, Core Research Institute, Jeju National University, Jeju 63243, Republic of Korea
*saydur_pr@yahoo.com
*yskoh7@jejunu.ac.kr
30 June 2025. pp. 111-119
PDF XML Citation
Abstract

Canadian, American, and European guidelines and authorities recommend fosfomycin for managing acute uncomplicated cystitis. Fosfomycin is the main treatment option for multidrug-resistant (MDR) Gram-negative bacterial infections. Fosfomycin (C3H7O4P) is a member of the epoxide family and a derivative of phosphonic acid, with a molecular weight of 138 Da. Fosfomycin is an antibacterial drug that acts against both Gram-positive and -negative bacteria and is structurally unrelated to any other antibiotic class currently in use. Fosfomycin was developed in the late 1960s; however, fosfomycin use has experienced a resurgence owing to its ability to effectively combat various extensively drug-resistant (XDR) and MDR diseases, which is due to its distinct mode of action and wide range of activity. Enterobacteriaceae-related disease requires treatment with combination therapy owing to Enterobacteriaceae acquiring various antibiotic resistance genes through plasmids and mobile elements. Additionally, the emergence of fosfomycin-resistance genes in isolates originating from humans, animals, food, and the environment has raised concerns about the potential for the spread of these bacteria, particularly Salmonella and Escherichia coli, at the interfaces among humans, animals, and the environment. Many in vitro studies have focused on combining fosfomycin and carbapenems; however, additional pharmacokinetic, pharmacodynamic, and clinical studies are required to maximize the use of fosfomycin.

Keywords
Membrane transport pathway
Cystitis
Multidrug resistance
Antibiotic resistance
References
1

Rahman MS, Amin GMA, Anwar SM, Azam MF, Akhter F, Islam MR, et al. Plazomicin-a new aminoglycoside-for treating complicated urinary tract infections. J Bacteriol Virol. 2023;53(1):1-10.

10.4167/jbv.2023.53.1.001
2

Rahman MS, Shathi SS, Amin GMA, Akhter F, Azam MF, Akter S, et al. Eravacycline, the first and unique fluorocycline antibacterial agent. J Bacteriol Virol. 2024;54(1):1-11.

10.4167/jbv.2024.54.1.001
3

Rahman MS, Koh YS. Delafloxacin, a new miracle in antibiotics armamentarium for bacterial infections. J Bacteriol Virol. 2019;49(1):39-43.

10.4167/jbv.2019.49.1.39
4

Rahman MS, Koh YS. Omadacycline, a magic antibiotics for bacterial infections. J Bacteriol Virol. 2018;48(3):109-112.

10.4167/jbv.2018.48.3.109
5

Rahman MS, Koh YS. A novel antibiotic agent, cefiderocol, for multidrug-resistant Gram-negative bacteria. J Bacteriol Virol. 2020;50(4):218-226.

10.4167/jbv.2020.50.4.218
6

Zurfluh K, Treier A, Schmitt K, Stephan R. Mobile fosfomycin resistance genes in Enterobacteriaceae-an increasing threat. Microbiology Open. 2020;9(12):e1135.

10.1002/mbo3.113533128341PMC7755807
7

Raz R. Fosfomycin: an old-new antibiotic. Clin Microbiol Infect. 2012;18(1):4-7.

10.1111/j.1469-0691.2011.03636.x21914036
8

Falagas ME, Athanasaki F, Voulgaris GL, Triarides NA, Vardakas KZ. Resistance to fosfomycin: mechanisms, frequency and clinical consequences. Int J Antimicrob Agents. 2019;53(1):22-28.

10.1016/j.ijantimicag.2018.09.01330268576
9

Dijkmans AC, Zacarías NVO, Burggraaf J, Mouton JW, Wilms EB, van Nieuwkoop C, et al. Fosfomycin: pharmacological, clinical and future perspectives. Antibiotics. 2017;6(4):6040024.

10.3390/antibiotics604002429088073PMC5745467
10

Zhang Y, Lin X, Bush K. In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline. J Antibiot (Tokyo). 2016;69(8):600-604.

10.1038/ja.2016.7327353166
11

Bassetti M, Righi E, Carnelutti A, Graziano E, Russo A. Multidrug-resistant Klebsiella pneumoniae: challenges for treatment, prevention and infection control. Expert Rev Anti Infect Ther. 2018;16(10):749-761.

10.1080/14787210.2018.152224930207815
12

Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis. 2010;10(1):43-50.

10.1016/S1473-3099(09)70325-120129148
13

Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis. 2008;46(7):1069-1077.

10.1086/52744218444827
14

Aminov RI. A brief history of the antibiotic era: lessons learned and challenges for the future. Front Microbiol. 2010;1:134.

10.3389/fmicb.2010.00134PMC3109405
15

Joukhadar C, Klein N, Dittrich P, Zeitlinger M, Geppert A, Skhirtladze K, et al. Target site penetration of fosfomycin in critically ill patients. J Antimicrob Chemother. 2003;51(5):1247-1252.

10.1093/jac/dkg18712668580
16

Roussos N, Karageorgopoulos DE, Samonis G, Falagas ME. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents. 2009;34(6):506-515.

10.1016/j.ijantimicag.2009.08.01319828298
17

Scherberich JE, Fünfstück R, Naber KG. Urinary tract infections in patients with renal insufficiency and dialysis - epidemiology, pathogenesis, clinical symptoms, diagnosis and treatment. GMS Infect Dis. 2021;9:Doc07.

18

Zhanel GG, Walkty AJ, Karlowsky JA. Fosfomycin: a first-line oral therapy for acute uncomplicated cystitis. Can J Infect Dis Med Microbiol. 2016;2016:2082693.

10.1155/2016/208269327366158PMC4904571
19

Popovic M, Steinort D, Pillai S, Joukhadar C. Fosfomycin: an old, new friend? Eur J Clin Microbiol Infect Dis. 2010; 29(2):127-142.

10.1007/s10096-009-0833-219915879
20

Woodyer RD, Shao Z, Thomas PM, Kelleher NL, Blodgett JA, Metcalf WW, et al. Heterologous production of fosfomycin and identification of the minimal biosynthetic gene cluster. Chem Biol. 2006;13(11):1171-1182.

10.1016/j.chembiol.2006.09.00717113999
21

Wenzler E, Bleasdale SC, Sikka M, Bunnell KL, Finnemeyer M, Rosenkranz SL, et al. Phase I study to evaluate the pharmacokinetics, safety, and tolerability of two dosing regimens of oral fosfomycin tromethamine in healthy adult participants. Antimicrob Agents Chemother. 2018;62(8):e00464-18.

10.1128/AAC.00464-1829891606PMC6105781
22

Zhanel GG, Cheung D, Adam H, Zelenitsky S, Golden A, Schweizer F, et al. Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs. 2016;76(5):567-588.

10.1007/s40265-016-0545-826863149
23

Duez JM, Mousson C, Siebor E, Péchinot A, Freysz M, Nathalie S, et al. Fosfomycin and its application in the treatment of multidrug-resistant Enterobacteriaceae infections. Clin Med Rev Ther. 2011;3:123-142.

10.4137/CMRT.S5102
24

Wenzler E, Bleasdale SC, Sikka MK, Bunnell K, Finnemeyer M, Rosenkranz SL, et al. Phase I study to evaluate the pharmacokinetics of two dosing regimens of oral fosfomycin tromethamine in healthy adult participants. Open Forum Infect Dis. 2017;4(Suppl 1):S529.

10.1093/ofid/ofx163.1377
25

Mazzei T, Cassetta MI, Fallani S, Arrigucci S, Novelli A. Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections. Int J Antimicrob Agents. 2006;28:S35-41.

10.1016/j.ijantimicag.2006.05.01916829051
26

Docobo-Pérez F, Drusano GL, Johnson A, Goodwin J, Whalley S, Ramos-Martín V, et al. Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance. Antimicrob Agents Chemother. 2015;59(9):5602-5610.

10.1128/AAC.00752-1526124169PMC4538498
27

Sastry S, Clarke LG, Alrowais H, Querry AM, Shutt KA, Doi Y. Clinical appraisal of fosfomycin in the era of antimicrobial resistance. Antimicrob Agents Chemother. 2015;59(12):7355-7361.

10.1128/AAC.01071-1526369978PMC4649162
28

Sastry S, Doi Y. Fosfomycin: resurgence of an old companion. J Infect Chemother. 2016;22(5):273-280.

10.1016/j.jiac.2016.01.01026923259PMC4833629
29

Rhodes NJ, Gardiner BJ, Neely MN, Grayson ML, Ellis AG, Lawrentschuk N, et al. Optimal timing of oral fosfomycin administration for pre-prostate biopsy prophylaxis. J Antimicrob Chemother. 2015;70(7):2068-2073.

10.1093/jac/dkv06725802286
30

Ongün Ş, Aslan G, Avkan-Oguz V. The effectiveness of single-dose fosfomycin as antimicrobial prophylaxis for patients undergoing transrectal ultrasound-guided biopsy of the prostate. Urol Int. 2012;89(4):439-444.

10.1159/00034237023006631
31

Gardiner BJ, Mahony AA, Ellis AG, Lawrentschuk N, Bolton DM, Zeglinski PT, et al. Is fosfomycin a potential treatment alternative for multidrug-resistant Gram-negative prostatitis? Clin Infect Dis. 2014;58(4):e101-5.

10.1093/cid/cit70424170195
32

Fiadjoe P, Kannan K, Rane A. Maternal urological problems in pregnancy. Eur J Obstet Gynecol Reprod Biol. 2010;152(1):13-17.

10.1016/j.ejogrb.2010.04.01320483528
33

Usta TA, Dogan O, Ates U, Yucel B, Onar Z, Kaya E. Comparison of single‐dose and multiple‐dose antibiotics for lower urinary tract infection in pregnancy. Int J Gynecol Obstet. 2011;114(3):229-233.

10.1016/j.ijgo.2011.03.01421696732
34

Krcmery S, Hromec J, Demesova D. Treatment of lower urinary tract infection in pregnancy. Int J Antimicrob Agents. 2001;17(4):279-282.

10.1016/S0924-8579(00)00351-411295408
35

Rudenko N, Dorofeyev A. Prevention of recurrent lower urinary tract infections by long-term administration of fosfomycin trometamol. Double blind, randomized, parallel group, placebo controlled study. Arzneimittelforschung. 2005;55(7):420-427.

10.1055/s-0031-129688116080282
36

Legat FJ, Maier A, Dittrich P, Zenahlik P, Kern T, Nuhsbaumer S, et al. Penetration of fosfomycin into inflammatory lesions in patients with cellulitis or diabetic foot syndrome. Antimicrob Agents Chemother. 2003;47(1):371-374.

10.1128/AAC.47.1.371-374.200312499216PMC148983
37

Forestier F, Salvanet-Bouccara A, Leveques D, Junes P, Rakotondrainy C, Dublanchet A, et al. Ocular penetration kinetics of fosfomycin administered as a one-hour infusion. Eur J Ophthalmol. 1996;6(2):137-142.

10.1177/1120672196006002078823585
38

Walkty A, Lagacé-Wiens PR, Karlowsky JA, Hoban DJ, Manickam K, Adam H, et al. Change in antimicrobial susceptibility of Escherichia coli urinary tract isolates at a single institution over a period of 10 years. Can J Microbiol. 2012;58(3):345-349.

10.1139/w2012-00122369590
39

Karlowsky JA, Lagacé-Wiens PRS, Simner PJ, DeCorby MR, Adam HJ, Walkty A, et al. Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study. Antimicrob Agents Chemother. 2011;55(7):3169-3175.

10.1128/AAC.00066-1121537027PMC3122429
40

Ling W, Paterson DL, Harris PNA, Furuya-Kanamori L, Edwards F, Laupland KB. Population-based incidence and characteristics of adult Escherichia coli bloodstream infection in Queensland, Australia, from 2000 to 2019. Open Forum Infect Dis. 2023;10(3):ofad071.

10.1093/ofid/ofad07136968960PMC10034595
41

Joukhadar C, Klein N, Dittrich P, Zeitlinger M, Geppert A, Skhirtladze K, et al. Target site penetration of fosfomycin in critically ill patients. J Antimicrob Chemother. 2003;51(5):1247-1252.

10.1093/jac/dkg18712668580
42

Karageorgopoulos DE, Wang R, Yu XH, Falagas ME. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother. 2012;67(2):255-268.

10.1093/jac/dkr46622096042
43

Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103-120.

10.1093/cid/ciq25721292654
44

Knothe H, Schäfer V, Sammann A, Shah PM. Influence of fosfomycin on the intestinal and pharyngeal flora of man. Infection. 1991;19(1):18-20.

10.1007/BF016437512013503
45

Florent A, Chichmanian RM, Cua E, Pulcini C. Adverse events associated with intravenous fosfomycin. Int J Antimicrob Agents. 2011;37(1):82-83.

10.1016/j.ijantimicag.2010.09.00221074377
46

Kawaki H, Takagi T, Fujiwara H, Sasaki Y. Nuclear magnetic resonance studies of acid-base association in solution. II. Association between ketones and tris(dipivaloylmethanato)europium. Chem Pharm Bull (Tokyo). 1981;29(9):2397-2402.

10.1248/cpb.29.2397
47

Yoshiyama Y, Yamaguchi K, Matsuo K, Kurokawa M, Kanke M. The effect of fosfomycin on nedaplatin-induced nephrotoxicity in rats. J Infect Chemother. 2005;11(1):14-17.

10.1007/s10156-004-0361-Z15729482
48

Langford PR, Harpur ES, Kayes JB, Gonda I. Studies of a potential in vitro test for estimation of toxicity of aminoglycoside antibiotics and polyamines. J Antibiot (Tokyo). 1982;35(10):1387-1393.

10.7164/antibiotics.35.13877174522
Information
  • Publisher :The Korean Society for Microbiology and The Korean Society of Virology
  • Publisher(Ko) :대한미생물학회‧대한바이러스학회
  • Journal Title :JOURNAL OF BACTERIOLOGY AND VIROLOGY
  • Volume : 55
  • No :2
  • Pages :111-119
  • Received Date : 2025-05-19
  • Revised Date : 2025-05-29
  • Accepted Date : 2025-05-30
  • DOI :https://doi.org/10.4167/jbv.2025.55.2.111
Journal Informaiton JOURNAL OF BACTERIOLOGY AND VIROLOGY JOURNAL OF BACTERIOLOGY AND VIROLOGY
  • NRF
  • 임플란트학회 전용 배너
  • KOFST
  • crossref crossmark
  • crossref cited-by
  • crossref funder-registry
  • crosscheck
  • orcid
  • open access
  • ccl
Journal Informaiton Journal Informaiton - close